Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy BioMarin Pharmaceutical stock in Canada | $77.3
Own BioMarin Pharmaceutical shares in just a few minutes.
BioMarin Pharmaceutical is a biotechnology business based in the US. BioMarin Pharmaceutical stocks (BMRN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $83.91 – a decrease of 0.39% over the previous week. BioMarin Pharmaceutical employs 3,059 staff and has a trailing 12-month revenue of around $1.9 billion.
How to buy BioMarin Pharmaceutical stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: BMRN in this case.
- Research BioMarin Pharmaceutical stocks. The platform should provide the latest information available.
- Buy your BioMarin Pharmaceutical stocks. It's that simple.
What's in this guide?
- Can I buy shares in BioMarin Pharmaceutical?
- Has coronavirus impacted BioMarin Pharmaceutical shares?
- BioMarin Pharmaceutical shares summary
- Compare share dealing platforms
- Is BioMarin Pharmaceutical stock a buy or sell?
- BioMarin Pharmaceutical performance over time
- Can I short BioMarin Pharmaceutical shares?
- Is BioMarin Pharmaceutical suitable for ethical investing?
- Are BioMarin Pharmaceutical shares over-valued?
- BioMarin Pharmaceutical's financials
- How volatile are BioMarin Pharmaceutical shares?
- Does BioMarin Pharmaceutical pay a dividend?
- Other common questions
How has Coronavirus impacted BioMarin Pharmaceutical's stock price?
Since the stock market crash in March caused by coronavirus, BioMarin Pharmaceutical's stock price has had significant negative movement.
Its last market close was $77.3, which is 18.77% down on its pre-crash value of $95.16 and 13.26% up on the lowest point reached during the March crash when the stocks fell as low as $68.25.
If you had bought $1,000 worth of BioMarin Pharmaceutical stocks at the start of February 2020, those stocks would have been worth $849.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $919.87.
BioMarin Pharmaceutical stock priceUse our graph to track the performance of BMRN stocks over time.
BioMarin Pharmaceutical stocks at a glance
|Latest market close||$77.3|
|52-week range||$71.35 - $124.5199|
|50-day moving average||$81.4727|
|200-day moving average||$80.1972|
|Wall St. target price||$107.11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$4.402|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy BioMarin Pharmaceutical stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
BioMarin Pharmaceutical price performance over time
|1 month (2021-07-02)||-9.56%|
|3 months (2021-04-30)||-0.80%|
Is BioMarin Pharmaceutical under- or over-valued?
Valuing BioMarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioMarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioMarin Pharmaceutical's P/E ratio
BioMarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, BioMarin Pharmaceutical stocks trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.
BioMarin Pharmaceutical's PEG ratio
BioMarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7902. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioMarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
BioMarin Pharmaceutical's EBITDA
BioMarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$54.8 million.
The EBITDA is a measure of a BioMarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.
BioMarin Pharmaceutical financials
|Revenue TTM||USD$1.9 billion|
|Gross profit TTM||USD$708.1 million|
|Return on assets TTM||-0.61%|
|Return on equity TTM||22.39%|
|Market capitalisation||USD$14.1 billion|
TTM: trailing 12 months
How to short and sell BioMarin Pharmaceutical stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "BMRN.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 10.2 million BioMarin Pharmaceutical stocks held short by investors – that's known as BioMarin Pharmaceutical's "short interest". This figure is 3.3% down from 10.6 million last month.
There are a few different ways that this level of interest in shorting BioMarin Pharmaceutical stocks can be evaluated.
BioMarin Pharmaceutical's "short interest ratio" (SIR)
BioMarin Pharmaceutical's "short interest ratio" (SIR) is the quantity of BioMarin Pharmaceutical stocks currently shorted divided by the average quantity of BioMarin Pharmaceutical stocks traded daily (recently around 1.1 million). BioMarin Pharmaceutical's SIR currently stands at 9.39. In other words for every 100,000 BioMarin Pharmaceutical stocks traded daily on the market, roughly 9390 stocks are currently held short.
However BioMarin Pharmaceutical's short interest can also be evaluated against the total number of BioMarin Pharmaceutical stocks, or, against the total number of tradable BioMarin Pharmaceutical stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioMarin Pharmaceutical's short interest could be expressed as 0.06% of the outstanding stocks (for every 100,000 BioMarin Pharmaceutical stocks in existence, roughly 60 stocks are currently held short) or 0.0563% of the tradable stocks (for every 100,000 tradable BioMarin Pharmaceutical stocks, roughly 56 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against BioMarin Pharmaceutical.
Find out more about how you can short BioMarin Pharmaceutical stock.
BioMarin Pharmaceutical's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like BioMarin Pharmaceutical.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
BioMarin Pharmaceutical's total ESG risk score
Total ESG risk: 25.92
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and BioMarin Pharmaceutical's overall score of 25.92 (as at 01/01/2019) is nothing to write home about – landing it in it in the 42nd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like BioMarin Pharmaceutical is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
BioMarin Pharmaceutical's environmental score
Environmental score: 0.12/100
BioMarin Pharmaceutical's environmental score of 0.12 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that BioMarin Pharmaceutical is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
BioMarin Pharmaceutical's social score
Social score: 15.87/100
BioMarin Pharmaceutical's social score of 15.87 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that BioMarin Pharmaceutical is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
BioMarin Pharmaceutical's governance score
Governance score: 7.42/100
BioMarin Pharmaceutical's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that BioMarin Pharmaceutical is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
BioMarin Pharmaceutical's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. BioMarin Pharmaceutical scored a 1 out of 5 for controversy – the highest score possible, reflecting that BioMarin Pharmaceutical has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||25.92|
|Total ESG percentile||42.26|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||1|
BioMarin Pharmaceutical stock dividends
We're not expecting BioMarin Pharmaceutical to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
BioMarin Pharmaceutical stock price volatility
Over the last 12 months, BioMarin Pharmaceutical's stocks have ranged in value from as little as $71.35 up to $124.5199. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioMarin Pharmaceutical's is 0.5832. This would suggest that BioMarin Pharmaceutical's stocks are less volatile than average (for this exchange).
BioMarin Pharmaceutical overview
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
Stocks similar to BioMarin Pharmaceutical
BioMarin Pharmaceutical in the news
BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
BioMarin Pharmaceutical inc (BMRN) Q2 2021 Earnings Call Transcript
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to invest $1 million
Here are the top 5 ways you should invest $1 million.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada when it goes public
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.